family with sequence similarity 66 member BGenealiases: []
Q-omics provides the consensus-scored FAM66B profile across patient tissues and cancer cell-line models. FAM66B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM66B is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, FAM66B RNA expression shows 17,575 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where FAM66B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM66B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM66B survival associations across molecular data types. FAM66B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM66B RNA expression–survival associations across cancer types. High FAM66B expression shows unfavorable associations in THCA, LGG and LUAD, but favorable associations in ACC, BRCA and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for FAM66B RNA expression.
This table summarizes FAM66B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM66B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM66B shows lower tumor expression in THCA, BRCA, STAD, KICH and UCEC and higher tumor expression in KIRP. The THCA box plot shows higher FAM66B RNA expression in normal versus tumor tissue (log2 FC = −0.484, t-test p < 0.001).
This table shows molecular features associated with FAM66B in patient tissues and cancer cell lines. In patient samples, FAM66B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
